TL;DR
Get health and wellness essentials delivered free with Prime
- Fast, free delivery on millions of items
- Prime Video, Amazon Music and more included
- Member-only deals all year
Researchers examining a donated brain from one former Alzheimer’s trial participant found less tau buildup and tissue damage in areas where amyloid plaques had been cleared than in nearby areas where plaques remained. The unusual comparison may help explain how amyloid removal relates to other disease processes, but a single case cannot prove the treatment caused the differences.
Researchers examining the donated brain of a former Alzheimer’s clinical trial participant found much less tau buildup and tissue degeneration in regions where amyloid plaques had largely cleared than in nearby regions where plaques remained. The single-patient study, presented at the 2026 Alzheimer’s Association International Conference and published in JAMA, offers a rare human comparison but does not establish that plaque removal caused the difference.
The man was in his 50s when he was diagnosed with mild cognitive impairment caused by Alzheimer’s disease. He later received 30 doses of aducanumab over four and a half years in a clinical trial. He died about four years after his last dose, more than a decade after his first symptoms, and had asked for his brain to be donated to research.
Investigators found a patchwork pattern across neighboring parts of the brain. The raised folds, called gyri, had lost most of their amyloid plaques and contained little accumulated tau. The grooves between the folds, known as sulci, retained substantial amyloid and showed more tau tangles, inflammation and brain-tissue degeneration. Scans taken while the man was alive had also indicated that amyloid clearance varied by region.
The researchers say this side-by-side pattern allowed them to compare affected and less-affected areas within the same person. The study concerns one brain after one treatment course; it does not establish how often this pattern occurs or whether the same relationship applies to other patients or amyloid-targeting drugs.
What the Brain’s Regional Contrast Shows
The findings address a question in Alzheimer’s research: whether removing beta-amyloid plaques may also affect tau, a protein abnormality that accumulates inside neurons and is associated with damage to brain cells. In this case, areas with less amyloid also had less tau and degeneration, a pattern consistent with a possible link between plaque clearance and reduced damage from other disease processes.
That possibility matters as amyloid-targeting drugs are used to treat some people with Alzheimer’s. The study may inform how researchers think about treatment effects beyond plaque measurements alone. But the regional contrast cannot show that aducanumab produced the difference, nor can it establish a clinical benefit for patients. Other factors could have contributed, and the evidence comes from a single postmortem examination.
The results also raise a timing issue. The report notes that clinical trials often assess outcomes over roughly 18 months, while some effects might take longer to become apparent. Whether amyloid removal produces lasting protection, how much removal might be needed, and how those effects could be measured remain open research questions.
As an affiliate, we earn on qualifying purchases.
Why This Brain Was Unusual
Alzheimer’s disease is associated with two protein abnormalities. Beta-amyloid forms plaques outside nerve cells, while tau accumulates inside neurons in abnormal tangles. Both are linked to progressive brain-cell damage and problems with memory and thinking, though their relationship and sequence remain subjects of research.
Drugs designed to remove amyloid have changed Alzheimer’s treatment. Aducanumab, the medicine used in this case, received accelerated approval from the U.S. Food and Drug Administration and is no longer sold. Donanemab, marketed as Kisunla, and lecanemab, marketed as Leqembi, are newer amyloid-targeting medicines that have received full FDA approval, according to the source report.
Researchers have had limited opportunities to examine brain tissue after amyloid-clearing treatment. Many prior reports described either broad plaque clearance or limited clearance, rather than both patterns in neighboring areas of the same brain. The patient’s donation therefore provided a rare comparison; it does not make the case representative of people treated with these medicines generally.
“Seeing both disease patterns side-by-side in the same brain gave us a rare opportunity to understand how amyloid removal affects other proteins that contribute to Alzheimer’s disease.”
— David Wolk, MD, co-senior author and co-director of the Penn Memory Center
As an affiliate, we earn on qualifying purchases.
Limits of a Single Brain
The study cannot prove that amyloid clearance caused the lower tau levels or reduced degeneration in the affected regions. It examined one patient’s brain, and the source report does not establish whether the pattern would appear in other people or after treatment with other drugs.
Researchers also do not yet know how much plaque removal, if any particular amount, might be needed to affect tau, how long a potential effect could last, or whether the observed tissue differences correspond to a measurable difference in memory or daily function. The report describes a relationship between regional patterns, not proof of treatment effectiveness or a forecast for individual patients.
As an affiliate, we earn on qualifying purchases.
Questions for Further Research
The researchers say they hope to investigate the relationship between amyloid clearance, tau accumulation and brain damage further. The source report does not specify a timeline or describe a particular next study. Further cases and research would be needed to test whether the pattern seen here recurs and to distinguish a treatment effect from other explanations.
For now, the findings add a rare postmortem observation to evidence about amyloid-targeting treatment. They do not change what can be concluded from one case: whether thorough or early plaque removal slows Alzheimer’s progression, and how long any effect might last, remain unresolved.
As an affiliate, we earn on qualifying purchases.
Key Questions
What did researchers find in the donated brain?
Regions with little remaining amyloid had little tau buildup, while neighboring areas retaining amyloid showed more tau tangles, inflammation and tissue degeneration.
How many patients were included?
The report describes one patient, a former clinical trial participant whose brain was donated after his death.
Does the study prove aducanumab prevented brain damage?
No. The findings show a regional association in one brain. They cannot prove that treatment caused the differences in tau or degeneration.
What treatment did the patient receive?
He received 30 doses of aducanumab over four and a half years as part of a clinical trial, according to the report.
What remains unknown?
It is not clear whether the pattern occurs in other patients, how much amyloid removal might matter, or whether the tissue differences mean a lasting clinical benefit. More research is needed to answer those questions.
Source: rss
Fall Picks
fall essentials
As an affiliate, we earn on qualifying purchases.
